As of 2026-03-28, the EV/EBITDA ratio of Foghorn Therapeutics Inc. (FHTX) is -2.43. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FHTX's latest enterprise value is 183.27 mil USD. FHTX's TTM EBITDA according to its financial statements is -75.41 mil USD. Dividing these 2 quantities gives us the above FHTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.9x - 14.1x | 14.0x |
| Forward P/E multiples | 15.8x - 19.7x | 17.8x |
| Fair Price | (18.92) - (16.74) | (19.02) |
| Upside | -520.5% - -471.9% | -522.6% |
| Date | EV/EBITDA |
| 2026-03-27 | -2.43 |
| 2026-03-26 | -2.74 |
| 2026-03-25 | -2.76 |
| 2026-03-24 | -2.66 |
| 2026-03-23 | -2.89 |
| 2026-03-20 | -2.82 |
| 2026-03-19 | -2.73 |
| 2026-03-18 | -2.73 |
| 2026-03-17 | -2.87 |
| 2026-03-16 | -2.80 |
| 2026-03-13 | -2.74 |
| 2026-03-12 | -2.76 |
| 2026-03-11 | -3.33 |
| 2026-03-10 | -3.20 |
| 2026-03-09 | -3.19 |
| 2026-03-06 | -3.43 |
| 2026-03-05 | -3.32 |
| 2026-03-04 | -3.34 |
| 2026-03-03 | -3.22 |
| 2026-03-02 | -3.41 |
| 2026-02-27 | -3.35 |
| 2026-02-26 | -3.41 |
| 2026-02-25 | -3.44 |
| 2026-02-24 | -3.34 |
| 2026-02-23 | -3.40 |
| 2026-02-20 | -3.39 |
| 2026-02-19 | -3.47 |
| 2026-02-18 | -3.33 |
| 2026-02-17 | -3.26 |
| 2026-02-13 | -3.25 |
| 2026-02-12 | -3.02 |
| 2026-02-11 | -3.15 |
| 2026-02-10 | -3.17 |
| 2026-02-09 | -3.17 |
| 2026-02-06 | -3.35 |
| 2026-02-05 | -3.00 |
| 2026-02-04 | -3.31 |
| 2026-02-03 | -3.36 |
| 2026-02-02 | -3.48 |
| 2026-01-30 | -3.37 |
| 2026-01-29 | -3.42 |
| 2026-01-28 | -3.50 |
| 2026-01-27 | -3.52 |
| 2026-01-26 | -3.45 |
| 2026-01-23 | -3.50 |
| 2026-01-22 | -3.75 |
| 2026-01-21 | -3.66 |
| 2026-01-20 | -3.26 |
| 2026-01-16 | -3.61 |
| 2026-01-15 | -3.82 |